Home-administered transcranial direct current stimulation is a feasible intervention for depression

An observational cohort study

Datos Bibliográficos

ID15529668
AutoresLeigh Charvet (0000-0003-4429-9713, New York University, autor de correspondencia), Allan George (0000-0001-5949-8139, New York University), Erik Charlson (New York University), Matthew Lustberg (New York University), Amy Vogel-Eyny (0000-0002-0596-0575, New York University), Tehila Eilam‐Stock (Albert Einstein College of Medicine), Hyein Cho (New York University), Pamela Best (New York University), Luis E Fernandez (0000-0003-3879-1445, New York University), Abhishek Datta (0000-0002-6778-8125, City College of New York), Marom Bikson (0000-0002-0493-8333, City College of New York), Kamran Nazim (Soterix Medical (United States)), Giuseppina Pilloni (0000-0001-6226-5627, New York University)
Año2023
Volumen14
Páginas1199773-1199773
Fecha de publicación2023-08-22
Open AccessSí
TipoARTICLE
RevistaFrontiers in Psychiatry (JOURNAL)
Identificadores de la revistaISSN: 1664-0640 • E-ISSN: 1664-0640
EditorialFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2023.1199773
PMID37674552
OpenAlexW4386069185
IdiomaEN
Citas recibidas1
Referencias citadas4

Transcranial direct current stimulation (tDCS) is an emerging treatment for major depression. We recruited participants with moderate-to-severe major depressive episodes for an observational clinical trial using Soterix Medical's tDCS telehealth platform as a standard of care. The acute intervention consisted of 28 sessions (5 sessions/week, 6 weeks) of the left anodal dorsolateral prefrontal cortex (DLPFC) tDCS (2.0 mA × 30 min) followed by a tapering phase of weekly sessions for 4 weeks (weeks 7-10). The n = 16 completing participants had a significant reduction in depressive symptoms by week 2 of treatment [Montgomery-Åsberg Depression Rating Scale (MADRS), Baseline : 28.00 ± 4.35 vs. Week 2: 17.12 ± 5.32, p < 0.001] with continual improvement across each biweekly timepoint. Acute intervention responder and remission rates were 75 and 63% and 88 and 81% following the taper period (week 10)

Brain stimulation · Depression (economics · Observational study · Physical therapy · Randomized controlled trial · Rating scale · Stimulation · Transcranial Direct Current Stimulation · Electroconvulsive Therapy Studies · Functional Brain Connectivity Studies · Medicine · Psychology · Transcranial Magnetic Stimulation Studies · Internal Medicine

Herramientas

Abrir DOIOpen Access